Brought to you by 
Vermillion gets rights to Stanford's biomarker panel for PAD
08 Apr 2008
Executive Summary
Vermillion (diagnostics) has licensed exclusive worldwide development and marketing rights to Stanford University's biomarker panel to determine the risk of peripheral artery disease (PAD).
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vermillion gets rights to Stanford's biomarker panel for PAD
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice